



# The European research triggered by the COVID pandemic: the convalescent plasma domain



5.1.2e

European Commission  
DG Research and Innovation  
People Directorate  
'Combatting diseases'




# Horizon 2020 R&I against coronavirus



## 1. EU funding to combat COVID-19: focus on treatment, vaccines and crisis management

FIGURE 1: DISTRIBUTION OF COVID-19 H2020 PROJECTS ACCORDING TO MAJOR NEEDS BY ESTIMATED EU FINANCIAL CONTRIBUTION (M EURO)



Research and Innovation

469m€ for 105 COVID-related research projects




# Horizon 2020 R&I against coronavirus



1. EU funding to combat COVID-19: focus on treatment, vaccines and crisis management

FIGURE 1: DISTRIBUTION OF COVID-19 H2020 PROJECTS ACCORDING TO MAJOR NEEDS BY ESTIMATED EU FINANCIAL CONTRIBUTION (M EURO)



Research and Innovation

469m€ for 105 COVID-related research projects



SUPPORTing high quality evaluation of covid-19  
convalescent plasma throughout EUROPE

[www.support-e.eu](http://www.support-e.eu)  
[info@support-e.eu](mailto:info@support-e.eu)

## SUPPORTing high quality evaluation of COVID-19 convalescent Plasma throughout Europe

H2020 EU contribution €4 million

Coordination: European Blood Alliance (EBA)

12 participants (from The Netherlands, Germany, Italy, Belgium, Denmark, UK, Switzerland)

Start date: 1 July 2020 (duration 2y)

- **Assessing** CCP, conducting clinical evaluation and defining best practises.
- **Supporting** high quality clinical evaluation and producing datasets for inclusion and analysis in the EU-CCP database. Facilitating anti-SARS-CoV-2 antibody testing and establishing the relationship between antibody (Ab) content in donor plasma and clinical outcome.
- **Developing harmonised recommendations** on CCP collection, testing and therapeutic use to treat Covid-19 and paving the way to prepare for future epidemics/pandemics with novel pathogens across the EU.




Figure 1-1 - The SUPPORT-E project concept



## Achievements

### 01 Support high quality clinical evaluation of CCP throughout the EU

provides specific support to clinical trials and monitored access programmes, based on carried-out review and Guidance documents on assessment criteria. Up to now: 13 randomised and 9 non-randomised clinical trials have been selected.

### 02 EU-CCP Database

Open-access EU CCP database: gathers and makes available data on convalescent plasma donations and patient outcomes following transfusions. SUPPORT-E is promoting high-quality data sets in the EU CCP database by providing financial support for data submitted.

### 03 Assay calibration

Variability between tests across Europe has been mapped (questionnaire) on access to and nature of antibody testing and virus neutralization testing. Results: majority of respondents (20) did not have access (in house or outsourced) to live-virus or pseudotype neutralization testing. Only 9 reporting access.

### 04 Health Economics of COVID-19 plasma

In collaboration with Oxford University (Health Economics Research Centre), a consultation was carried out to evaluate the costs and benefits associated with CCP collection and testing using different strategies.

### 05 Opinion paper published in Vox Sanguinis

Evaluation of SARS-CoV-2 antibody titers and potency for convalescent plasma donation (*Wouters et al*). The paper describes the major issue(s) with testing of CCP for antibodies against SARS-CoV-2.

<https://onlinelibrary.wiley.com/doi/10.1111/vox.13060>



## In the pipeline..

### 01 COVID-19 trial proposal

A Randomized Open-Label Trial of Convalescent Plasma Therapy in Clinically Vulnerable Individuals with Mild COVID-19 (COVIC-19).  
COVIC-19 addresses some of the knowledge gaps identified

### 02 CCP neutralisation of variants / variants sequencing

Investigation for a potential collaborative work: SUPPORT-E to provide laboratory capacity to the emergence and spread of SARS-CoV-2 variants in Europe (to assess their potential effect to convalescent plasma efficacy).

### 03 Assay calibration

support to calibration and cross border standardization of assays in EU Member States (via distributing standards to the Blood Establishments identified in questionnaire and analyzing that data)

### 04 Developing recommendations and preparing for the future

SWOT analysis in terms of CCP collection, testing and use during the first wave of the COVID-19 crisis

### 05 SUPPORT of monitored access use programmes

With support of CA and clinicians, monitored access programmes will be contacted to assess the inclusion of monitored access use programmes in SUPPORT-E (operational aspects and financial support).

Research and  
Innovation



# AYAC

<https://covidantibodytherapy.info/>

## Antibody Therapy Against Coronavirus (COVID-19)

H2020 - EU contribution €3 million

Coordination: Karolinska University (KI)

5.1.2e

5 participants (Sweden, Germany, Italy, Belgium, Switzerland)

Start date: 1 March 2020 (duration 2y)

### Preclinical development of antibodies against SARS-CoV-2

ATAC uses a novel approach to immunotherapy development against COVID-19 by leveraging three different and independent methods:

- gamma-globulin immunotherapy (KI)
- Generation and selection human antibodies in the laboratory by library screening (Technische Universität Braunschweig (Germany))
- Selection of antibodies from convalescent plasma and *in vitro* optimisation to generate recombinant monoclonal antibodies (Institute of Research in Biomedicine (IRB))

Research and  
Innovation



## Antibody therapy against coronavirus (ATAC)

### Planned work

- To generate purified hyperimmune gammaglobulin batches from convalescent COVID-19 patients
- To evaluate the resulting gammaglobulin preparation for virus neutralization *in vitro*
- To test gammaglobulin in critically ill patients (compassionate use)

### Work performed

- **Follow the immune response in plasma of recovered individuals in Italy and Sweden**
  - Collect plasma from convalescent donors (mild to severe)
  - Follow IgM, IgG and IgA antibodies anti-RBD and anti-S-protein for a period of 6-8 months
  - Follow the neutralization activity against SARS-CoV-2 virus
  - Sherina *et al.* Med (in press)
- **Hyperimmune plasma therapy for treatment of critically ill patients in Italy**
  - Collect plasma from convalescent donors
  - Treatment of moderate to severe COVID-19 patients treated with hyperimmune plasma
  - Perotti *et al.* 2020. Haematologica 105:2834-2840






## Proof-of-concept study - hyperimmune plasma therapy

- One arm, multicenter interventional study on a short term (7 days) on 46 severe COVID patients.
  - March 25-April 28 (NCT04321421)
- Two university hospitals and one general hospital in Northern Italy
  - Fondazione IRCCS, Policlinico San Matteo

### Conclusions:

- Benefit of hyperimmune plasma in COVID-19 patients, both through a reduction of mortality, an improvement in respiratory function and decreases in inflammatory indices.
- Need to be confirmed in a larger randomized controlled trial



Home About REMAP-CAP COVID-19 The REMAP-CAP Team Resources Contact Us

REMAP-CAP

*A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia*

11,368	10,214	31
Patient randomisations	Patient randomisations with suspected or proven COVID-19	Available interventions in 12 Domains
6,110	5,312	296
Total patients	Patients with suspected or proven COVID-19	Active Sites

REMAP-CAP trial platform is supported by **5.1.2e** PREPARE, RECOVER and other funders

Research and Innovation

## COVID-19 domain

The Remap-Cap trial is investigating new therapies for severely ill COVID-19 patients.

Has enrolled over 4,000 patients in 290 clinical sites around the world.

Recently it reported that two arthritis drugs, tocilizumab and sarilumab, could potentially cut the relative risk of death among people in intensive care with Covid of 24%



## COVID-19 Domains

All participating sites will be able to participate in two existing domains that have relevance to the treatment of patients with severe CAP resulting from coronavirus. These are:

- Evaluation of prolonged macrolide therapy, as a modulator of immune function
- Evaluation of alternative corticosteroid strategies (no corticosteroids, low dose hydrocortisone for 7 days, or hydrocortisone while the patient is in septic shock)
- Evaluation of no antiviral therapy for COVID-19 (and no placebo), lopinavir/ritonavir (Kaletra), hydroxychloroquine, and the combination of hydroxychloroquine and lopinavir/ritonavir
- Evaluation of no immune-modulating therapy for COVID-19 (and no placebo), Interferon-beta-1a, interleukin-1 receptor antagonist (Anakinra), tocilizumab and sarilumab.
- Evaluation of the use of convalescent plasma for COVID-19
- Evaluating therapeutic dose anticoagulation using low molecular-weight heparin or unfractionated heparin compared to standard pharmacologic thromboprophylaxis
- Evaluation the use of high-dose vitamin C for patients with severe CAP including CAP caused by COVID-19
- Evaluation of the use of simvastatin for COVID-19
- Evaluation of the use of aspirin or a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) compared to no antiplatelet therapy
- Evaluation of angiotensin converting enzyme inhibitor (ACEi), angiotensin-II receptor blocker (ARB), an ARB in combination with a chemokine receptor-2 inhibitor, or no renin-angiotensin system inhibitor for patients with COVID-19

**NHSBT responsible  
trial management**




### Current status:

In January, REMAP-CAP trial **halted recruitment** to its convalescent plasma arm on the recommendation of the data safety monitoring board. An **interim analysis** that was based on data from **912 patients** found that the probability that convalescent plasma was beneficial was 2.2% (no benefit).

Analysis is still ongoing to assess whether plasma could benefit subgroups of patients (e.g. those with low natural antibody levels).

Some other international trials are also testing plasma effect when used very early in the disease, before people are hospitalized (already some evidence available). Similar trials are discussed in the UK and other EU countries.




The screenshot shows the top portion of the EVAg website. At the top, there is a blue banner with the European Union flag and the word "Europe". Below this is the website's header, which includes the EVAg logo (European Virus Archive - Global), a search bar, and navigation links for "Contact Us", "FAQs", and "Login / Register". The main navigation menu includes "HOME", "PORTAL", "THE PROJECT" (highlighted), and "PARTNERS". Social media icons for RSS, Facebook, Twitter, LinkedIn, and YouTube are also present.


The main content area features a dark background with the text "Home / The project" and "The EVAg project". Below this, the text reads: "EVAg is a non-profit organisation dedicated to the **distribution** of biological materials in the field of virology." This is followed by a paragraph: "For that purpose, EVAg maintains high control standards and develops appropriate methods directly relevant to human and animal virology. The EVAg consortium also ensures:"

- that materials are supplied non-profitably or at cost to all bona fide applicants,
- that biosafety and security measures are appropriately addressed by the supplying and recipient labs,
- that the available materials meet the highest scientific standards in terms of quality and characterization,
- that the property of the provided materials remains with the originators.

A blue button labeled "Browse our Catalogue" is positioned to the right of the list. At the bottom of the page, a blue box contains the text "Research and Innovation".




European Virus Archive - GLOBAL
Contact Us
FAQs
Login / Register

[HOME](#)
[PORTAL](#)
[THE PROJECT](#)
[PARTNERS](#)


Home / The project

# The EVAg project

EVAg is a non-profit organisation dedicated to the **distribution** of biological

- For that purpose, we provide relevant tools and resources:
- that make it easy to access
  - that are user-friendly
  - that are available to all
  - that are up-to-date



Our collection of SARS-CoV-2 variants and related products is regularly updated

**Visit Here**

The best way to get viral material within the *Scientific Community*. Browse our viruses and derived products from the EVAg Portal.

[Visit our Portal](#) or learn more.

Research and Innovation



# Thank you for your attention

## Coronavirus research and innovation

EU supported research and innovation projects and initiatives to tackle the spread of coronavirus and preparedness for other outbreaks.



The European Commission has been at the forefront of supporting research and innovation and coordinating European and global research efforts, including preparedness for pandemics.

In addition to a number of past and ongoing research actions related to coronavirus and outbreaks, the Commission launched several special actions in 2020.

These actions address epidemiology, preparedness and response to outbreaks, the development of diagnostics, treatment and vaccines, as well as the infrastructure and resources that enable this research.

The Commission and national ministers have also agreed on the first [EU&usCorona action plan](#) which lays out 10 priority areas and coordinated actions to tackle coronavirus. The action plan is available [here](#).

### PAGE CONTENTS

- Research and innovation areas
- Highlights
- Latest
- Documents
- Related links

### Research and innovation areas

- |  |   |
|--|---|
| <a href="#">Preparedness and response</a>              | <a href="#">Society, Economy, Behaviour</a>   |
| <a href="#">Diagnostics</a>                            | <a href="#">Gender equality</a>               |
| <a href="#">Treatments</a>                             | <a href="#">Global cooperation</a>            |
| <a href="#">Vaccines</a>                               | <a href="#">EU funding</a>                    |
| <a href="#">Equipment and manufacturing</a>            | <a href="#">Data, regulations, guidelines</a> |
| <a href="#">Medical Technologies and Digital tools</a> | <a href="#">Map of coronavirus reports</a>    |
| <a href="#">Infrastructure and resources</a>           | <a href="#">Manifesto for EU Research</a>     |

[https://ec.europa.eu/info/research-and-innovation/research-area/health-research-and-innovation/coronavirus-research-and-innovation\\_en](https://ec.europa.eu/info/research-and-innovation/research-area/health-research-and-innovation/coronavirus-research-and-innovation_en)

Research and Innovation